PMID- 29362869
OWN - NLM
STAT- MEDLINE
DCOM- 20180427
LR  - 20180517
IS  - 1435-702X (Electronic)
IS  - 0721-832X (Linking)
VI  - 256
IP  - 3
DP  - 2018 Mar
TI  - Antiplatelet and anticoagulant agents in vitreoretinal surgery: a prospective 
      multicenter study involving 804 patients.
PG  - 461-467
LID - 10.1007/s00417-017-3897-1 [doi]
AB  - PURPOSE: To assess the rate of hemorrhagic complications after vitreoretinal 
      surgery and the influence of antithrombotic agents. METHODS: Hemorrhagic 
      complications of vitreoretinal procedures performed in seven ophthalmologic 
      centers on patients treated or not treated with antiplatelet (AP) or 
      anticoagulant (AC) agents were prospectively collected. Patients' 
      characteristics, surgical techniques, and complications were recorded during 
      surgery and for 1 month after. RESULTS: Eight hundred four procedures were 
      performed between January 2015 and April 2015. Among them, 18.4% were treated 
      with AP agents (n = 148) and 7.8% with AC agents (n = 63), with 18 of them 
      treated with NOACS (new oral anticoagulants). AP or AC agents were continued in 
      96.5% and 80.7% of cases, respectively. Fifty-three patients (6.6%) developed one 
      or more hemorrhagic complications in one eye during this period. In univariate 
      analysis, AC agents were not associated with hemorrhagic complications 
      (P = 0.329) in contrast to AP (P = 0.005). However, in multivariate analysis, AP 
      agents were no longer associated with hemorrhagic complications and the 
      intraoperative use of endodiathermy was the only factor associated with 
      hemorrhagic complications (P = 0.001). CONCLUSIONS: This study showed that AP and 
      AC agents were not a factor associated with hemorrhagic complications during 
      vitreoretinal surgery. The continuation of these treatments should be considered 
      without risk of severe hemorrhagic complications.
FAU - Meillon, Cyril
AU  - Meillon C
AD  - Department of Ophthalmology, University Hospital, 14 rue Paul Gaffarel, 21079, 
      Dijon, France.
FAU - Gabrielle, Pierre Henry
AU  - Gabrielle PH
AD  - Department of Ophthalmology, University Hospital, 14 rue Paul Gaffarel, 21079, 
      Dijon, France.
FAU - Luu, Maxime
AU  - Luu M
AD  - Plurithematic Clinical Investigation Center (CIC-P) INSERM 803 and Department of 
      Medical Pharmacology, University Hospital, Dijon, France.
FAU - Aho-Glele, Ludwig S
AU  - Aho-Glele LS
AD  - Hospital Hygiene and Epidemiology Unit, University Hospital, Dijon, France.
FAU - Bron, Alain M
AU  - Bron AM
AUID- ORCID: 0000-0002-7265-931X
AD  - Department of Ophthalmology, University Hospital, 14 rue Paul Gaffarel, 21079, 
      Dijon, France. alain.bron@chu-dijon.fr.
AD  - Eye and Nutrition Research Group, CSGA, UMR 1324 INRA, 6265 CNRS, University of 
      Burgundy, Dijon, France. alain.bron@chu-dijon.fr.
FAU - Creuzot-Garcher, Catherine
AU  - Creuzot-Garcher C
AD  - Department of Ophthalmology, University Hospital, 14 rue Paul Gaffarel, 21079, 
      Dijon, France.
AD  - Eye and Nutrition Research Group, CSGA, UMR 1324 INRA, 6265 CNRS, University of 
      Burgundy, Dijon, France.
CN  - CFSR research net
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20180123
PL  - Germany
TA  - Graefes Arch Clin Exp Ophthalmol
JT  - Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
      Graefes Archiv fur klinische und experimentelle Ophthalmologie
JID - 8205248
RN  - 0 (Anticoagulants)
RN  - 0 (Platelet Aggregation Inhibitors)
SB  - IM
CIN - Graefes Arch Clin Exp Ophthalmol. 2018 Mar;256(3):627-629. PMID: 29075861
CIN - Graefes Arch Clin Exp Ophthalmol. 2018 Mar;256(3):459-460. PMID: 29344757
CIN - Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1359. PMID: 29602959
CIN - Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1357. PMID: 29602962
MH  - Aged
MH  - Anticoagulants/*administration & dosage
MH  - Blood Coagulation/*drug effects
MH  - Female
MH  - Follow-Up Studies
MH  - France/epidemiology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Platelet Aggregation Inhibitors/*administration & dosage
MH  - Postoperative Hemorrhage/*epidemiology/etiology
MH  - Prospective Studies
MH  - Retinal Diseases/blood/*surgery
MH  - Risk Factors
MH  - Vitreoretinal Surgery/*adverse effects
OTO - NOTNLM
OT  - Anticoagulants
OT  - Antiplatelet agents
OT  - Antithrombotic therapy
OT  - Vitreoretinal surgery
EDAT- 2018/01/25 06:00
MHDA- 2018/04/28 06:00
CRDT- 2018/01/25 06:00
PHST- 2017/09/19 00:00 [received]
PHST- 2017/12/29 00:00 [accepted]
PHST- 2017/11/08 00:00 [revised]
PHST- 2018/01/25 06:00 [pubmed]
PHST- 2018/04/28 06:00 [medline]
PHST- 2018/01/25 06:00 [entrez]
AID - 10.1007/s00417-017-3897-1 [pii]
AID - 10.1007/s00417-017-3897-1 [doi]
PST - ppublish
SO  - Graefes Arch Clin Exp Ophthalmol. 2018 Mar;256(3):461-467. doi: 
      10.1007/s00417-017-3897-1. Epub 2018 Jan 23.